As the industry re-evaluates how to conduct business in the midst of a global pandemic, new trends have emerged. In addition to a shift in how M& A is conducted, valuations are through the roof, and even depressed assets are sought after &mdash That&rsquo s Nice Managing Director Nigel Walker explains what&rsquo s changed and offers his predictions for the rest of the year. 

What&rsquo s left in the market right now is further consolidation. One such example would be Recipharm&rsquo s acquisition of Aesica and Consort Medical to create another ~$1.5 billion, fully integrated small molecule CDMO. Fareva acquired assets from Pierre Fabre for manufacturing monoclonal antibodies (mAbs) and for aseptic fill/finish, adding  to their operations and making Fareva a fully integrated small and large molecule drug product and drug substance CDMO &mdash joining only Thermo Fisher Scientific in that category group &mdash     and taking Fareva over the $2 billion mark. Similarly, Dow Pharma acquired assets from Famar, resulting in another $1 billion CDMO, and Piramal Pharma Solutions, a mid-tier CDMO with a global footprint focused on small molecule manufacturing, acquired a depressed OSD drug product facility from G& W Laboratories. 

16.2/16.3 is a good strategic point. from 25 nov went into a hibernation mode. both scm and kc like brothers, their threads went silence.
silence is the most wonderful time 😀 this december is going to be different b' cos everyone are celebrating thanksgiving and christmas at home.  not forgetting new year. back in those days when they have nothing to do, they make babies. 
woah .... awesome december.
imho

Keppel Land to divest remaining 30% stake in Dong Nai Waterfront City